Innovent Biologics. has filed a patent for novel proteins with heterodimeric antibody Fc, like bispecific antibodies, and innovative methods for their production. The claim describes a heterodimeric Fc scaffold with specific CH3 region sequences to enhance interactions. GlobalData’s report on Innovent Biologics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Innovent Biologics, Nanoparticle drug conjugates was a key innovation area identified from patents. Innovent Biologics's grant share as of January 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Patent filed for novel heterodimeric fc scaffold proteins
See Also:
The patent application (Publication Number: US20240034795A1) describes a novel heterodimeric Fc scaffold designed for enhanced stability and binding properties. The scaffold consists of two Fc regions, each with unique CH3 regions that interact heterodimerically to provide stronger binding compared to homodimeric interactions. The specific mutations in the CH3 regions, such as S364R+D399K and K370S+Y349T+K409D, contribute to this enhanced interaction. Additionally, the scaffold may include mutations like T350V and amino acid sequences from parent CH3 regions to further optimize stability and binding affinity.
Furthermore, the patent application details the use of this heterodimeric Fc scaffold in creating Fc heterodimers with improved target-binding capabilities. These Fc heterodimers can bind to various antigens or receptors, including PD1, PDL1, CD20, and IL-2R, among others. The application also covers methods for producing these Fc heterodimers in vitro, involving the assembly of target-binding regions with the unique Fc scaffold. Overall, the invention aims to provide a versatile platform for developing novel therapeutics with enhanced binding properties and stability, potentially impacting the fields of antibody engineering and drug development.
To know more about GlobalData’s detailed insights on Innovent Biologics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
